Phase 3 Readout
ORIC: Phase 3 Topline: A Phase 3, Randomized, Open-Label Study of Rinzimetostat (ORIC-944) in Combination With Darolutamide
September 1, 2030 · rinzimetostat. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- September 1, 2030
- Company
- Oric Pharmaceuticals, Inc. (ORIC)
- Drug
- rinzimetostat
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Phase 3, Randomized, Open-Label Study of Rinzimetostat (ORIC-944) in Combination With Darolutamide
- Drug
- rinzimetostat